Keyphrases
Radioimmunotherapy
100%
90Y-ibritumomab Tiuxetan
100%
Gastrointestinal Follicular Lymphoma
100%
Treatment Options
16%
Low Risk
16%
Gastrointestinal Tract
16%
External Beam Radiotherapy
16%
Lymphoma Cells
16%
Hematotoxicity
16%
Toxicity Profile
16%
Chelator
16%
Follicular Lymphoma
16%
Relapse-free
16%
Curative Treatment
16%
Shortest Path Length
16%
Radioimmunoconjugate
16%
Gastrointestinal Toxicity
16%
Anti-CD20 Antibody
16%
Indolent Course
16%
High-intensity Radiation
16%
Radioisotopes
16%
Case Series Report
16%
Medicine and Dentistry
Follicular Lymphoma
100%
Radioimmunotherapy
100%
Ibritumomab Tiuxetan
100%
Disease
14%
Rituximab
14%
External Beam Radiotherapy
14%
Lymphoma Cell
14%
Radioisotope
14%
Gastrointestinal Tract
14%
Gastrointestinal Toxicity
14%
Chelating Agent
14%
Pharmacology, Toxicology and Pharmaceutical Science
Follicular Lymphoma
100%
Ibritumomab Tiuxetan
100%
Radioisotope
14%
Rituximab
14%
Gastrointestinal Toxicity
14%
Disease
14%
Chelating Agent
14%